September 4, 2020
Kyowa Kirin said on September 3 that the biosimilar version of the cancer agent Rituxan (rituximab) from its strategic collaborator Sandoz has received approval in Japan for additional indications of chronic idiopathic thrombocytopenic purpura and as premedication of ibritumomab tiuxetan...read more